Prism Medico and Pharmacy Limited has announced the approval of its unaudited standalone financial results for the quarter and half year ended September 30, 2026. The Board of Directors convened on November 5, 2026, to review and approve these results, which were prepared in accordance with Indian Accounting Standards. The company also provided its standalone statement of assets and liabilities and cash flow statement for the respective periods.
Financial Results Approved by Board
Prism Medico and Pharmacy Limited has officially announced the approval of its unaudited standalone financial results for the quarter and the half-year period that concluded on September 30, 2026. This significant decision was made during a meeting of the company’s Board of Directors held on November 5, 2026. The meeting commenced at 03:30 P.M. and concluded at 05:30 P.M., during which the Board reviewed and sanctioned these financial statements.
Key Financial Highlights
The financial results, which have been subject to a limited review by the company’s auditors, reflect the company’s performance for the specified periods. Notably, the company reported a Net Profit of ₹22.65 Lakhs for the quarter ended September 30, 2026, a significant improvement from the net loss of ₹5.84 Lakhs in the corresponding quarter of the previous year. For the half-year period ended September 30, 2026, the company posted a Net Profit of ₹16.81 Lakhs, compared to a Net Loss of ₹8.48 Lakhs in the same period last year.
Statement of Assets and Liabilities
The company also presented its Statement of Assets and Liabilities as of September 30, 2026. Total assets stood at ₹3,329.07 Lakhs, with non-current assets accounting for ₹14.99 Lakhs and current assets amounting to ₹3,314.08 Lakhs. On the liabilities side, total equity was ₹3,311.96 Lakhs, and current liabilities were ₹17.11 Lakhs. The company’s Equity Share Capital was reported at ₹1,356.34 Lakhs.
Cash Flow Analysis
The Cash Flow Statement for the half-year ended September 30, 2026, reveals a positive Net Cash from Operating Activities of ₹(93.80) Lakhs. The company generated significant cash from financing activities, primarily through the issuance of share warrants, amounting to ₹1,749.98 Lakhs. This resulted in a substantial Net Increase in Cash and Cash Equivalents of ₹1,656.18 Lakhs for the period.
Source: BSE
